Literature DB >> 18629465

[Therapy of acute myocardial infarction in the prehospital setting].

H R Arntz1.   

Abstract

The time period from symptom onset to hospital admission is of outstanding importance for the prognosis of a patient with an acute myocardial infarction. He is threatened by sudden cardiac death triggered by ventricular fibrillation on the one hand and on the other hand this period offers the chance for a timely decision on the optimal reperfusion strategy. A broad spectrum of therapeutic opportunities regarding thrombolysis, antiplatelets and anticoagulation has been proven to be effective in large randomised trials and registries. These results should influence the individual decision on reperfusion treatment as well as the patient's conditions, time lines, logistics and local resources.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629465     DOI: 10.1007/s00108-008-2073-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  30 in total

1.  Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.

Authors:  Mariann Gyöngyösi; Hans Domanovits; Werner Benzer; Moritz Haugk; Birgit Heinisch; Gottfried Sodeck; Ronald Hödl; Georg Gaul; Gerhard Bonner; Johann Wojta; Anton Laggner; Dietmar Glogar; Kurt Huber
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

2.  Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.

Authors: 
Journal:  Lancet       Date:  2006-02-18       Impact factor: 79.321

3.  Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Authors:  Z M Chen; L X Jiang; Y P Chen; J X Xie; H C Pan; R Peto; R Collins; L S Liu
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

4.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.

Authors: 
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

5.  Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.

Authors:  Uwe Zeymer; Ralf Zahn; Rudolf Schiele; Wolfgang Jansen; Ernst Girth; Anselm Gitt; Karlheinz Seidl; Rolf Schröder; Steffen Schneider; Jochen Senges
Journal:  Eur Heart J       Date:  2005-04-27       Impact factor: 29.983

6.  Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis.

Authors:  Brahmajee K Nallamothu; Eric R Bates; Jeph Herrin; Yongfei Wang; Elizabeth H Bradley; Harlan M Krumholz
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

7.  Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial.

Authors:  Arnoud W J van 't Hof; Nicolette Ernst; Menko-Jan de Boer; Rob de Winter; Eric Boersma; Ton Bunt; Sonia Petronio; A T Marcel Gosselink; Walter Jap; Frans Hollak; Jan C A Hoorntje; Harry Suryapranata; Jan-Henk E Dambrink; Felix Zijlstra
Journal:  Eur Heart J       Date:  2004-05       Impact factor: 29.983

8.  Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.

Authors:  Marc S Sabatine; David A Morrow; Anthony Dalby; Mathias Pfisterer; Tibor Duris; Jose Lopez-Sendon; Sabina A Murphy; Runlin Gao; Elliott M Antman; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-05-25       Impact factor: 24.094

Review 9.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  Epidemiology of avoidable delay in the care of patients with acute myocardial infarction in Italy. A GISSI-generated study. GISSI--Avoidable Delay Study Group.

Authors: 
Journal:  Arch Intern Med       Date:  1995-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.